Consensus $1.26B. Narrows FY24 revenue view to up 7%-9% from up 6%-9%, consensus $1.26B. Sees FY24 free cash flow $170M-$180M. Sees FY23 adjusted operating margin 21%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HAE:
- Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- HAE Upcoming Earnings Report: What to Expect?
- Opsens downgraded to Market Perform from Outperform at Raymond James
- Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
- Haemonetics to acquire Opsens for C$2.90 per share in cash, sees accretion
